Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 10/2007

01.10.2007 | Bone and Soft Tissue Sarcomas

Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite neo-adjuvant chemotherapy osteosarcomas having significant mortality, recent studies have shown survival advantages following infections for some tumour types. This study investigates the effect of post-operative infection in patients treated for osteosarcoma using endoprosthetic replacement and neo-adjuvant chemotherapy.

Material and Methods

A consecutive series of 547 patients underwent surgery between 1981 and 2001 for osteosarcoma. Patients were excluded from the study if over 60 years old at diagnosis (n = 14) as they would not routinely receive chemotherapy. Studies showed that 70% of deep infections occur within one year from reconstruction. Therefore landmark analysis was performed; all patients infected after 12 months of reconstruction were excluded (15 patients, 2.7%) and those who died within 12 months from diagnosis due to metastases were excluded (105 patients, 19.2%), leaving 412 patients. Any survival advantage of early infection was analysed by Kaplan-Meier survival analysis from this landmark point.

Results

Overall population survival was 65% at 10 years after landmarking. There were 41 patients (10%) who developed an infection within one year of implantation. These patients had significantly better survival (p = 0.017). The 10-year survival for patients with osteosarcoma with infection was 84.5% compared to 62.3% in the non-infected group after landmarking. There was no significant difference in the percentage post-chemotherapy specimen necrosis between the two groups (p = 0.36). Infection was an independent prognostic factor on cox regression analysis.

Conclusions

There was evidence for increased survival after deep post-operative infection in osteosarcoma patients, in keeping with other research. The authors feel this warrants further investigation.
Literatur
1.
Virkus WW, Marshall D, Enneking WF, Scarborough MT. The effect of contaminated surgical margins revisited. Clin Orthop Relat Res 2002;397:89–94PubMedCrossRef
2.
Rech A, Castro CG Jr, Mattei J, Gregianin L, Di Leone L, David A, Rivero LF, Tarrago R, Abreu A, Brunetto AL. Clinical features in osteosarcoma and prognostic implications. J Pediatr (Rio J) 2004; 80(1):65–70CrossRef
3.
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106(5):1154–61PubMedCrossRef
4.
Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg Am 2002; 84-A(1):49–57PubMed
5.
Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer 2005; 41(18):2846–52. Epub 2005 Nov 7PubMedCrossRef
6.
Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer 1998; 82(5):851–9PubMedCrossRef
7.
Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14(3):848–58PubMed
8.
Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, Armen T, Plager C, Papadopoulos NE, Edeiken J. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987; 4(3):212–36PubMed
9.
Juergens H, Kosloff C, Nirenberg A, Mehta BM, Huvos AG, Rosen G. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr. 1981; (56):221–6PubMed
10.
Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002; 84(1):88–92PubMedCrossRef
11.
Rodriguez-Galindo C, Shah N, McCarville MB, Billups CA, Neel MN, Rao BN, Daw NC. Outcome after local recurrence of osteosarcoma: the St. Jude Children’s Research Hospital experience (1970–2000). Cancer 2004; 100(9):1928–35PubMedCrossRef
12.
Grimer RJ, Sommerville S, Warnock D, Carter S, Tillman R, Abudu A, Spooner D. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005; 41(4):578–83; Epub 2005 Jan 5PubMedCrossRef
13.
Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12(2):423–31PubMed
14.
Jeys LM, Grimer RJ, Carter SR, Tillman RM. Periprosthetic infection in patients treated for an orthopaedic oncological condition’. J Bone Joint Surg Am 2005; 87-A(4):842–9CrossRef
15.
Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC, Withrow SJ. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol 2005; 12(12):1073–83.; Epub 2005 Oct 28PubMedCrossRef
16.
Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. European Osteosarcoma Intergroup; The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001; 37(1):39–46PubMedCrossRef
17.
Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38:163–170PubMedCrossRef
18.
Dupont WD, Plummer WD. Power and sample size calculations: a review and computer orogram. Controlled Clinical Trials 1990;11:116–28PubMedCrossRef
19.
Thrall DE, Withrow SJ, Powers BE, Straw RC, Page RL, Heidner GL, Richardson DC, Bissonnette KW, Betts CW, DeYoung DJ. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990; 18(6):1351–7PubMed
20.
Wiemann B, Starnes CO. Coley’s toxins, tumour necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64(3): 529–64PubMedCrossRef
21.
American Cancer Society. Guide to complementary & alternative cancer methods. Atlanta: American Cancer Society Inc.; 2000
22.
Shear MJ, Turner FC. Chemical treatment of tumours; isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prodigious) culture filtrate. J Natl Cancer Inst 1943; 4:81–7
23.
Algire GH, Legallais FY, Park HD. Vascular reactions of normaland malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigious) culture filtrates. J Natl Cancer Inst 1947; 8:53–62
24.
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 1975; 72:3666–70PubMedCrossRef
25.
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724–9PubMedCrossRef
26.
Hobohm U. Fever therapy revisited. Br J Cancer 2005; 92:421–5PubMed
27.
Challis G, Stam H. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 1990; 29(5):545–50PubMed
28.
Vermeire K, Schols D. Specific CD-4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74(5):667–75PubMedCrossRef
29.
Sensenig DM, Rossi NP, Ehrenhaft JL. Pulmonary resection for bronchogenic carcinoma in geriatric patients. Ann Thorac Surg 1966; 2:508–13PubMedCrossRef
30.
Ruckdesche l JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972; 287:1013–7CrossRef
31.
Schantz SP, Skolnik EM, O’Neill JV. Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. Otolaryngol Head Neck Surg 1980; 88:412–7PubMed
32.
Koelmel K, Pfahlberg A, Mastrangelo G, Niin M, Botev I, Seebacher C, Schneider D, Lambert D, Shafir R, Kokoschka E, Kleeberg U, Henz B, Gefeller O. Infections and melanoma risk: results of a multicenter EORTC case study. Melanoma Res 1999; 9:511–519CrossRef
33.
Krone B, Kolmel KF, Grange JM, Mastrangelo G, Hez BM, Botev IN, Niin M, Seebacher C, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A. Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case control study. Eur J Cancer. 2004; 39(16):2372–8CrossRef
34.
Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689–94PubMedCrossRef
35.
Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumour necrosis alpha based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer. 2006; 106(1):156–62PubMedCrossRef
36.
Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. TNF-based isolated limb perfusion of unresectable extremity desmoid tumours. Eur J Surg Oncol 2005; 31(8):912–8PubMedCrossRef
37.
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724–9PubMedCrossRef
38.
Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45:491–503PubMedCrossRef
39.
Hibbs Jr JB, Lambert Jr LH, Remington JS. Resistance to murine tumours conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis 1971; 124:587–92PubMed
40.
Hibbs Jr JB, Lambert Jr LH, Remington JS. Control of carcinogenesis: a possible role for the activated macrophage. Science 1972; 177:998–1000PubMedCrossRef
41.
Hibbs Jr JB, Lambert Jr LH, Remington JS. Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol 1972; 235:48–50PubMed
42.
43.
North RJ, Kirstein DP. T-cell-mediated concomitant immunity to syngeneic tumours. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumours and bacterial parasites. J Exp Med 1977; 145:275–92PubMedCrossRef
44.
Youdim S, Sharman M. Resistance to tumor growth mediated by Listeria monocytogenes: collaborative and suppressive macrophagelymphocyte interactions in vitro. J Immunol 1976; 117:1860–5PubMed
45.
Keller R, Keist R, Leist TP, van der Meide PH. Resistance to a non-immunogenic tumor, induced by Corynebacterium parvum or Listeria monocytogenes, is abrogated by anti-interferon γ. Int J Cancer 1990; 46:687–90PubMedCrossRef
46.
Hunter CA, Yu D, Gee M, Ngo C, Sevignani C, Goldscmidt M. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumours during acute toxoplasmosis. J Immunol 2001; 166:5878–81PubMed
47.
Thomas-Tikhonenko A, Hunter CA. Infection and cancer: the common vein Cytokine Growth Factor Rev. 2003; 14:67–77CrossRef
48.
Mori K, Redini F, Gouin F, Cherrier B, Heymann D. Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep 2006; 15(3):693–700PubMed
49.
Muller R, Sigbjorn S, Bauer H, Saeter G, Strander H. Interferon-a as the only adjuvant treatment in high-grade Osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncologica 2005; 44:475–80PubMedCrossRef
50.
Inaba H, Glibetic M, Buck S, Ravindranath Y, Kaplan J. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up regulating Fas receptors and caspase-8. Pediatr Blood Cancer 2004; 43(7):729–36PubMedCrossRef
51.
Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, Alvarez P, Halbert G, Durrant LG. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005; 92(8):1358–65PubMedCrossRef
52.
Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2006; 2(3):333–43. ReviewPubMedCrossRef
53.
Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006; 6(2):123–33. ReviewPubMedCrossRef
54.
Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML,Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23(9):2004–11PubMedCrossRef
55.
Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm 1999; 14(2):121–8PubMedCrossRef
56.
Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995; 1(12):1595–601PubMed
Metadaten
Titel
Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
Publikationsdatum
01.10.2007
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9483-8

Weitere Artikel der Ausgabe 10/2007

Annals of Surgical Oncology 10/2007 Zur Ausgabe

Breast Oncology

Occult Breast Lesion Localization plus Sentinel Node Biopsy (SNOLL): Experience with 959 Patients at the European Institute of Oncology

Bone and Soft Tissue Sarcomas

Dermatofibrosarcoma Protuberans: Recent Clinical Progress

Melanomas

Isolated Tumor Cells in the Sentinel Node Affect Long-Term Prognosis of Patients with Melanoma

ReviewPaper

Talc Pleurodesis for Malignant Pleural Effusions Is Preferred Over the Pleurx Catheter (Contrary Position)

Gastrointestinal Oncology

Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy?

Breast Oncology

Clinicopathologic Features and Long-Term Outcomes of 293 Phyllodes Tumors of the Breast

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.